双氯芬酸钠联合尪痹片治疗骨性关节炎的不良反应分析

The Analysis of Adverse Reaction of Osteoarthritis Cured by Diclofenac Potassium Combined with Wangbi Tables

目的:探讨在骨性关节炎治疗中使用尪痹片与双氯芬酸钠联合疗法的安全性。方法:从2012年3月-2014年1月笔者所在医院收治的骨性关节炎患者中选取84例为研究对象,按照随机数字表法分为观察组42例和对照组42例,两组均行常规治疗,对照组在此基础上加用双氯芬酸钠,观察组采用尪痹片联合双氯芬酸钠,观察两组患者不良反应发生情况。结果:观察组不良反应发生率为7.14%,与对照组的23.81%比较,明显较低,差异有统计学意义(P<0.05)。结论:在骨性关节炎治疗中,使用尪痹片和双氯芬酸钠联合治疗,具有较好协作性,可减少不良反应发生,提高治疗安全性。

Objective：To probe into the safety effects of osteoarthritis cured by Diclofenac Potassium combined with Wangbi Tablets.Method：84 patients who suffered from the osteoarthritis and who accepted treatments in our hospital from March 2012 to January 2014 were selected as the research objects,and these patients were randomly divided into the control group and the observation group by random digits table, 42 cases in each group. They were treated with conventional therapy.The control group on the basis of the treatment,they were treated with Diclofenac Potassium,while the observation group was treated with Wangbi Tablets combined with Diclofenac Potassium.The incidence of adverse reactions of two groups were observed. Result：The incidence rate of the observation group was 7.14%,was evidently lower than 23.81% of the control group,the difference had statistical significance（P〈0.05）.Conclusion：In the treatment of osteoarthritis that using Diclofenac Potassium combined with Wangbi Tablets has a good enough, which has a good cooperation and it can reduce the incidence of adverse reactions,and enhances the security of treatment.